SCHEMBL2827316

SCHEMBL2827316

CCOC(=O)c1c(C=Cc2cccc(OC(F)F)c2OCC(C)(C)C)nc2sccn12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 4/20 0.43
ALDH1A1 P00352 4/20 0.34
KDM4E B2RXH2 3/20 0.34
HPGD P15428 3/20 0.34
HSD17B10 Q99714 2/20 0.34
RECQL P46063 1/20 0.34
TP53 P04637 2/20 0.33
SMN1; SMN2 Q16637 4/20 0.32
RXFP1 Q9HBX9 2/20 0.32
HTT P42858 1/20 0.32
RAB9A P51151 3/20 0.32
MAPT P10636 3/20 0.32
LMNA P02545 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
KMT2A Q03164 1/20 0.31
HCRTR1 O43613 1/20 0.31
ALOX15 P16050 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2827313 1.00 MAPK1 (0.43) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2829848 0.90 HTT (0.34) MAPK1KDM4EHPGDSMN1; SMN2RXFP1
SCHEMBL2829845 0.90 HTT (0.34) MAPK1KDM4EHPGDSMN1; SMN2RXFP1
SCHEMBL2823980 0.90 MAPK1 (0.46) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2823984 0.90 MAPK1 (0.46) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2822592 0.89 MAPK1 (0.43) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2822595 0.89 MAPK1 (0.43) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2826793 0.88 MAPK1 (0.43) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2826796 0.88 MAPK1 (0.43) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2830607 0.86 MAPK1 (0.46) MAPK1ALDH1A1KDM4EHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318928-B2 Fused imidazole carboxamides as TRPV3 modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2012-11-27 US disclosed
US-20100152192-A1 FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS S.A (CH) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152192-A1 FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS TRPV3, TRPV1, TRPV2 MAPK1 2141/4885ALDH1A1 2705/4885KDM4E 3190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.